Market News AIOpen the app

The FDA has quickly approved GSK's Nelkarmi for treating ALK-positive lung cancer.

TrialRead the original at marketscreener.com
Good for GSK

The FDA's approval lets eligible patients use Nelkarmi now. This adds a treatment option to GSK's cancer business, though the report gives no sales estimate or patient count to show the size of the gain.

GSK · GlaxoSmithKline

AI read · Good for GSK

The AI's read

This gives patients with a specific lung cancer another treatment option and adds to GSK's cancer portfolio. The report gives no sales estimate or patient count, so the size of the benefit is unknown.

Get alerts for GSK

Follow GlaxoSmithKline (GSK) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GSK
Free on the App Store and Google Play, or on the web.